Skip to main content
Premium Trial:

Request an Annual Quote

Kreatech, Oridis Team on DNA-FISH Assays

NEW YORK (GenomeWeb News) – Kreatech Diagnostics and Oridis Biomarkers today said that they will co-develop and commercialize DNA-FISH assays for oncology applications.

The firms intend to develop the assays as companion diagnostics for pharmaceutical firms conducting pre-clinical and clinical development of new compounds. Amsterdam, The Netherlands--based Kreatech said that it expects to begin commercializing assays in the second half of this year.

According to the partners, the first assay developed under the collaboration will detect amplification of the fibroblast growth factor receptor 1 gene, which has been implicated in several cancer types including lung, breast, prostate, and bladder cancers.

"By using Oridis' expertise in clinical testing and its access to extensive bio banks we have the opportunity to bring our customized FISH4U program to the next level," Kreatech CEO Kees Moonen said in a statement. "With this collaboration we are able to contribute to successful clinical development of novel pharmaceutical compounds as well as to the development of companion diagnostics."

Terms of the collaboration agreement were not disclosed.

Oridis is a contract research organization based in Graz, Austria. It specializes in cancer research and offers biomarker evaluation, patient stratification, antibody profiling, and diagnostic assay development services.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.